Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | RARG | P13631 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6342590 | 0.81 | RARG (0.36) | PTGS2RARGRXRAPPARGTSHR | |
| SCHEMBL13452000 | 0.78 | RARG (0.37) | PTGS2RARGRXRAPPARGTSHR | |
| SCHEMBL2947022 | 0.75 | PTGS2 (0.47) | PTGS2RARGRXRAPPARGTSHR | |
| SCHEMBL6338177 | 0.73 | RARG (0.47) | RARGRXRAPPARGTSHRCYP3A4 | |
| SCHEMBL12706039 | 0.71 | RARG (0.39) | PTGS2RARGRXRAPPARGTSHR | |
| SCHEMBL13688744 | 0.70 | ALDH1A1 (0.42) | PTGS2RARGRXRAPPARGTSHR | |
| SCHEMBL14817161 | 0.70 | RARG (0.40) | PTGS2RARGRXRAPPARGTSHR | |
| SCHEMBL6339245 | 0.70 | RARG (0.33) | RARGRXRAPPARGTSHRCYP3A4 | |
| SCHEMBL10019863 | 0.69 | CYP3A4 (0.42) | PTGS2RARGRXRAPPARGTSHR | |
| SCHEMBL6676891 | 0.69 | PTGS2 (0.42) | PTGS2RARGRXRAPPARGTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849658-B2 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2005-02-01 | — | — | US | disclosed |
| US-20030216586-A1 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | GALDERMA RESEARCH & DEVELOPMENT | 2003-11-20 | — | — | US | disclosed |
| EP-0977749-B1 | BI-AROMATIC COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RES & DEV (FR) | 2002-03-13 | — | — | EP | disclosed |
| US-6346546-B1 | COMPOUNDS HAVING MARKED ACTIVITY IN FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION; TREATING SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-02-12 | — | — | US | disclosed |
| US-6103762-A | A BIAROMATIC COMPOUNDS IN WHICH THE AROMATIC NUCLEI ARE CONNECTED BY A PROPYNYLENE OR ALLENYLENE DIVALENT RADICAL, USEFUL AS HUMAN OR VETERINARY MEDICINE OR USED IN COSMETICS OR KERATINIZATION DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2000-08-15 | — | — | US | disclosed |
| EP-0977749-A1 | BI-AROMATIC COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | Galderma Research & Development (FR) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998056783-A1 | BI-AROMATIC COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RESEARCH & DEVELOPMENT (FR) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216586-A1 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | AR, SRR, MC3R | PTGS2 4315/4885RARG 136/4885RXRA 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.